Literature DB >> 19182054

Sexual risk behaviour of the first cohort undergoing screening for enrollment into Phase I/II HIV vaccine trials in South Africa.

K M Andersson1, R M Van Niekerk, L M Niccolai, O N Mlungwana, I M Holdsworth, M Bogoshi, J A McIntyre, G E Gray, E Vardas.   

Abstract

We assessed risk behaviour in a heterosexual cohort undergoing prescreening for the first Phase I/II HIV vaccine trials in Soweto. We developed a survey and collected self-reported data from HIV-negative potential volunteers. Of 488 participants, most were single and approximately half were from households with incomes below the poverty level. Males reported higher rates of heavy alcohol use (P < 0.001), marijuana use (P < 0.001) and other recreational drug use (P < 0.01). Males reported more sex partners than females in the previous six months (P < 0.001), as well as more casual/anonymous partners (P < 0.001) and one-night stands (P < 0.001). Multivariate analyses revealed substance use and male gender predicted higher risk behaviours, including <100% condom use with known/suspected HIV-positive partners, having casual/anonymous partners and having more than two partners. For this population, male volunteers may need increased risk-reduction counselling during Phase I/II trials and additional recruitment methods may be necessary to identify high-risk female volunteers for Phase III efficacy trials.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19182054      PMCID: PMC3556817          DOI: 10.1258/ijsa.2008.008207

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  18 in total

1.  NIMH/APPC workgroup on behavioral and biological outcomes in HIV/STD prevention studies: a position statement.

Authors:  W Pequegnat; M Fishbein; D Celentano; A Ehrhardt; G Garnett; D Holtgrave; J Jaccard; J Schachter; J Zenilman
Journal:  Sex Transm Dis       Date:  2000-03       Impact factor: 2.830

Review 2.  Social factors that make South African women vulnerable to HIV infection.

Authors:  Leáne Ackermann; KlerkGerhardtW de
Journal:  Health Care Women Int       Date:  2002-02

Review 3.  Ethical issues in HIV vaccine trials in South Africa.

Authors:  C Slack; G Lindegger; E Vardas; L Richter; A Strode; D Wassenaar
Journal:  S Afr J Sci       Date:  2000-06       Impact factor: 2.197

4.  Unique risks to volunteers in HIV vaccine trials.

Authors:  Sharon E Frey
Journal:  J Investig Med       Date:  2003-02       Impact factor: 2.895

5.  Randomized controlled trial of audio computer-assisted self-interviewing: utility and acceptability in longitudinal studies. HIVNET Vaccine Preparedness Study Protocol Team.

Authors:  D S Metzger; B Koblin; C Turner; H Navaline; F Valenti; S Holte; M Gross; A Sheon; H Miller; P Cooley; G R Seage
Journal:  Am J Epidemiol       Date:  2000-07-15       Impact factor: 4.897

6.  The HIV vaccine paradox.

Authors:  J Cohen
Journal:  Science       Date:  1994-05-20       Impact factor: 47.728

7.  Exposure efficacy and change in contact rates in evaluating prophylactic HIV vaccines in the field.

Authors:  M E Halloran; I M Longini; M J Haber; C J Struchiner; R C Brunet
Journal:  Stat Med       Date:  1994-02-28       Impact factor: 2.373

8.  Future access to HIV vaccines. Report from a WHO-UNAIDS Consultation, Geneva, 2-3 October 2000.

Authors: 
Journal:  AIDS       Date:  2001-05-04       Impact factor: 4.177

9.  Ethical, behavioral, and social aspects of HIV vaccine trials in developing countries.

Authors:  P Lurie; M Bishaw; M A Chesney; M Cooke; M E Fernandes; N Hearst; E Katongole-Mbidde; S Koetsawang; C P Lindan; J Mandel
Journal:  JAMA       Date:  1994-01-26       Impact factor: 56.272

10.  Condom effectiveness for reducing transmission of gonorrhea and chlamydia: the importance of assessing partner infection status.

Authors:  Lee Warner; Daniel R Newman; Harland D Austin; Mary L Kamb; John M Douglas; C Kevin Malotte; Jonathan M Zenilman; Judy Rogers; Gail Bolan; Martin Fishbein; David G Kleinbaum; Maurizio Macaluso; Thomas A Peterman
Journal:  Am J Epidemiol       Date:  2004-02-01       Impact factor: 4.897

View more
  7 in total

1.  Scaling up circumcision programs in Southern Africa: the potential impact of gender disparities and changes in condom use behaviors on heterosexual HIV transmission.

Authors:  Kyeen M Andersson; Douglas K Owens; A David Paltiel
Journal:  AIDS Behav       Date:  2011-07

Review 2.  Heterosexual anal intercourse: a neglected risk factor for HIV?

Authors:  Rebecca F Baggaley; Dobromir Dimitrov; Branwen N Owen; Michael Pickles; Ailsa R Butler; Ben Masse; Marie-Claude Boily
Journal:  Am J Reprod Immunol       Date:  2012-12-24       Impact factor: 3.886

Review 3.  Changing trends and the impact of alcohol on the HIV/AIDS epidemic in South Africa: review.

Authors:  Mashiko Setshedi; Suzanne M de la Monte
Journal:  SAHARA J       Date:  2011

4.  Anticipated changes in sexual risk behaviour following vaccination with a low-efficacy HIV vaccine: survey results from a South African township.

Authors:  K M Andersson; E Vardas; L M Niccolai; R M Van Niekerk; M M Mogale; I M Holdsworth; M Bogoshi; J A McIntyre; G E Gray
Journal:  Int J STD AIDS       Date:  2012-10       Impact factor: 1.359

5.  How common and frequent is heterosexual anal intercourse among South Africans? A systematic review and meta-analysis.

Authors:  Branwen N Owen; Jocelyn Elmes; Romain Silhol; Que Dang; Ian McGowan; Barbara Shacklett; Edith M Swann; Ariane van der Straten; Rebecca F Baggaley; Marie-Claude Boily
Journal:  J Int AIDS Soc       Date:  2017-01-12       Impact factor: 5.396

6.  Reported oral and anal sex among adolescents and adults reporting heterosexual sex in sub-Saharan Africa: a systematic review.

Authors:  Imran O Morhason-Bello; Severin Kabakama; Kathy Baisley; Suzanna C Francis; Deborah Watson-Jones
Journal:  Reprod Health       Date:  2019-05-06       Impact factor: 3.223

7.  Experiences on recruitment and retention of volunteers in the first HIV vaccine trial in Dar es Salam, Tanzania - the phase I/II HIVIS 03 trial.

Authors:  Muhammad Bakari; Patricia Munseri; Joel Francis; Eric Aris; Candida Moshiro; David Siyame; Mohamed Janabi; Mary Ngatoluwa; Said Aboud; Eligius Lyamuya; Eric Sandström; Fred Mhalu
Journal:  BMC Public Health       Date:  2013-12-09       Impact factor: 3.295

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.